Leticia G. León

EDUCATION

  • MS in Bioinformatics (2012 January)
    Vrije Universiteit Amsterdam (VU).
    De Boelelaan 1083A – 1081 HV Amsterdam – Netherlands
    Tutors: Anton Feestra and Jaap Heringa
  • Biochemistry and Molecular Biology, Cum Laude PhD (2005 May)
    Dpto. Biochemistry and Molecular Biology
    Universidad Complutense de Madrid
    Title of Thesis: Gene transference to canine haematopoietic precursors
    Prof. Concepcion Tejero Ortego
    Project: Graft vs. Host reactions against minor histocompatibility antigens on canine hematopoietic precursor cells as a preclinical model of graft vs. Leukemia reactions”. Funded by Deutsche José Carreras Leukämie-Stiftung e.v.
  • Advance Degree in Pharmacy, Pharm. D (1999 Sept)
    Universidad de Alcalá de Henares

POSITIONS HELD

  • Research position (01/02/2016-present)
    AIRC iCARE Marie Curie Fellowship to work as Responsible of the Bioinformatics Unit at Cancer Pharmacology Lab – AIRC Start-Up Unit, Pisa (Italy)
  • Research position (01/07/2013-30/11/2015)
    Responsible of the Bioinformatics Unit at La Laguna University.
    Center for Biomedical Research of the Canary Islands, Instituto de Tecnologias Biomédicas, Universidad de La Laguna
    Funded by FP7-REGPOT-2012-CT2012-31637-IMBRAIN
  • Hematology Molecular Lab (01/10/2012-30/06/2013)
    Hospital Universitario de Gran Canaria Dr. Negrin
  • Postdoctoral position, flow cytometry and molecular and cellular biology expert (01/01/2008-31/07/2012)
    BioLab, Instituto Universitario de BioOrganica AG
    Universidad de La Laguna
    Funded by FIS (Fondo de Insvestigación sanitaria) ISCIII. Sara Borrell Grant
  • Master Student internship (10/01/2011-10/06/2011)
    Structural Biology and Biocomputing Programme, Structural Computational Biology Group
    Spanish National Cancer Research Center, CNIO
    Funded by FIS (Fondo de Insvestigación sanitaria) ISCIII. Sara Borrell Grant
  • Postdoctoral position, flow cytometry and molecular and cellular biology (19/01/2009-27/07/2010)
    Oncology department, Medical Center Vrije Universiteit
    Cancer Center Amsterdam
    Funded by FIS (Fondo de Insvestigación sanitaria) ISCIII. Sara Borrell Grant
  • Collaborator position, Bibliography curator for decision support technologies in health service (01/07/2007-31/12/2007)
    Secretaria general del Servicio Canario de Salud
    Funded by Fondo de Investigación Sanitaria (FIS), ISCIII.
  • Postdoctoral position, flow cytometry and molecular and cellular biology expert (01/01/2006-31/06/2007)
    BioLab, Instituto Universitario de BioOrganica AG
    Universidad de La Laguna
    Funded by Fundacion Canaria de Investigacion del Cancer, FICIC.
  • Postdoctoral position, flow cytometry and molecular and cellular biology expert (01/07/2005-31/12/2005)
    Research Unit
    Hospital Universitario de Nuestra Señora de Candelaria

FURTHER COURSES

  • Specialization course in flow cytometry
    This course was organized by CIEMAT in collaboration with the UCM, in Madrid (Spain) (Frist Class) 37 hours during one week. 2001.
  • Spanish Ministry of Health “B” level certification for experiments and manipulation of animals (5 or more years of experience). Annex I to resolution of the General Directorate of Livestock, October 19, 2006, concerning the approval expected in the third transitory provision of RD 1201/2005 of 10 October, on the protection of animals used for experimental and other scientific purposes, published in the BOE No 252 of 21 October 2005.
  • Specialization Course in Molecular Oncology
    Pharmacology fields, 6 months. This course was organized in collaboration of ICIC, Prometeo’s Program and ULL, Spain (First Class) 250 hours. La Laguna, 2006. This course was funding by FEDER program (EU).

PUBLICATIONS

(chronological order since 2013)

  1. Maftouh M, Avan A, Sciarrillo R, Granchi C, Leon LG, Rani R, Funel N, Smid K, Honeywell R, Boggi U, Minutolo F, Peters GJ, Giovannetti E. Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. Br J Cancer. 2013 Oct 31. doi: 10.1038/bjc.2013.681
  2. Maietta P, Lopez G, Carro A, Pingilley BJ, Leon LG, Valencia A, Tress ML. FireDB: a compendium of biological and pharmacologically relevant ligands. Nucleic Acids Res. 2013. PubMed PMID: 24243844.
  3. Giovannetti E, Leon LG. New strategies and applications for drugs targeting EGFR and c-Met. Curr Drug Targets. 2014;15(14):1261-2.
  4. Leon LG, Gemelli M, Sciarrillo R, Avan A, Funel N, Giovannetti E. Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells. Curr Drug Targets. 2014;15(14):1331-40.
  5. Vasile E, Tibaldi C, Leon GL, D’Incecco A, Giovannetti E. Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients. J Cancer Res Clin Oncol. 2015 Jul;141(7):1189-94.
  6. Galvani E, Sun J, Leon LG, Sciarrillo R, Narayan RS, Tjin Tham Sjin R, Lee K, Ohashi K, Heideman DA, Alfieri RR, Heynen GJ, Bernards R, Smit EF, Pao W, Peters GJ, Giovannetti E. NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor. Oncotarget. . 2015 Dec 15;6(40):42717-32
  7. Cedrón JC, Ravelo ÁG, León LG, Padrón JM, Estévez-Braun A. Antiproliferative and Structure Activity Relationships of Amaryllidaceae Alkaloids. Molecules. 2015 Jul 30;20(8):13854-63.
  8. Santarpia M, Rolfo C, Peters GJ, Leon LG, Giovannetti E. On the pharmacogenetics of non-small cell lung cancer treatment. Expert Opin Drug Metab Toxicol. 2016 Mar;12(3):307-17.
  9. Leon LG, Funel N, Peters GJ, Avan A, Vistoli F, Boggi U, Giovannetti E. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Letter. Clin Cancer Res. 2016 May 15;22(10):2594.